Charles Wagner - Vertex Pharmaceuticals CFO, Executive Vice President

VRTX -- USA Stock  

Fiscal Quarter End: December 31, 2019  

  President
Mr. Charles F. Wagner was appointed as Chief Financial Officer, Executive Vice President of the company. Effective April 10, 2019
Age: 47  President Since 2019  MBA    
617 341-6100  www.vrtx.com
Wagner joins Vertex from Ortho Clinical Diagnostics, Inc. ? a Carlyle Group portfolio company, where he served as CFO and EVP, Finance. In this role, he had leadership responsibilities for all aspects of finance, accounting, tax, treasury, global information systems, lender relations, and acquisitions and divestitures, as well as shared responsibility for several enterprisewide projects. Prior to this, Mr. Wagner served as CFO for publicly traded Bruker Corporationrationrationration, Progress Software Corporationrationrationration and Millipore Corporationrationrationration. In addition to his corporate finance roles, Mr. Wagner served as an advisor at Bain & Company and Coopers & Lybrand. He received his BS in accounting from Boston ` and his MBA from Harvard Business School.

Management Efficiency

The company has return on total asset (ROA) of 8.3 % which means that it generated profit of $8.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 51.75 % meaning that it created $51.75 on every $100 dollars invested by stockholders.
The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Raghav ChariDr Reddys Laboratories Ltd
2013
Glenn DavidZoetis
2016
Michael AbermanRegeneron Pharmaceuticals
2015
Samiran DasDr Reddys Laboratories Ltd
2016
Kristin PeckZoetis
2018
Cartikeya ReddyDr Reddys Laboratories Ltd
2016
Catherine KnuppZoetis
2012
Joyce LeeZoetis
2012
Jay MarkowitzRegeneron Pharmaceuticals
2017
James MichaudPerrigo Company Plc
2016
Marion McCourtRegeneron Pharmaceuticals
2018
Saumen ChakrabortyDr Reddys Laboratories Ltd
2018
Amit BiswasDr Reddys Laboratories Ltd
2016
Alok SonigDr Reddys Laboratories Ltd
2015
J RamachandranDr Reddys Laboratories Ltd
2016
Jeffrey NeedhamPerrigo Company Plc
2009
Umang VohraDr Reddys Laboratories Ltd
2013
Heidi ChenZoetis
2012
Michael StewartPerrigo Company Plc
2004
Jatin ShahPerrigo Company Plc
2005
Sandra BeatyZoetis
2012

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run Cryptocurrency Center Now

   

Cryptocurrency Center

Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
All  Next Launch Module

Also Currentnly Active

Purchased few shares of
a day ago
Traded for 26.59
Purchased few shares of
a day ago
Traded for 175.48
Purchased few shares of
a day ago
Traded for 17.11
Also please take a look at World Market Map. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Search macroaxis.com